Connor Clark & Lunn Investment Management Ltd. Takes $3.68 Million Position in Zentalis Pharmaceuticals, Inc. $ZNTL

Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 758,033 shares of the company’s stock, valued at approximately $3,676,000.

Other large investors have also added to or reduced their stakes in the company. GSA Capital Partners LLP bought a new stake in shares of Zentalis Pharmaceuticals during the second quarter valued at approximately $1,815,000. Seven Fleet Capital Management LP bought a new position in Zentalis Pharmaceuticals in the 1st quarter valued at about $257,000. Anfield Capital Management LLC lifted its holdings in shares of Zentalis Pharmaceuticals by 239.9% in the fourth quarter. Anfield Capital Management LLC now owns 242,605 shares of the company’s stock valued at $328,000 after purchasing an additional 171,228 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Zentalis Pharmaceuticals by 182.6% during the first quarter. Dimensional Fund Advisors LP now owns 272,034 shares of the company’s stock valued at $634,000 after buying an additional 175,771 shares during the last quarter. Finally, 5AM Venture Management LLC boosted its position in shares of Zentalis Pharmaceuticals by 705.7% during the fourth quarter. 5AM Venture Management LLC now owns 3,947,913 shares of the company’s stock valued at $5,330,000 after buying an additional 3,457,913 shares during the last quarter.

Zentalis Pharmaceuticals Price Performance

NASDAQ:ZNTL opened at $3.80 on Friday. The company has a market cap of $272.35 million, a P/E ratio of -1.95 and a beta of 1.92. The stock’s fifty day moving average price is $4.37 and its two-hundred day moving average price is $3.72. Zentalis Pharmaceuticals, Inc. has a 1 year low of $1.21 and a 1 year high of $6.95.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its earnings results on Thursday, August 6th. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.10). On average, analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.14 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Zentalis Pharmaceuticals news, major shareholder Group Walters bought 4,335,000 shares of the firm’s stock in a transaction on Friday, August 14th. The shares were acquired at an average cost of $3.50 per share, for a total transaction of $15,172,500.00. Following the purchase, the insider directly owned 17,844,973 shares of the company’s stock, valued at $62,457,405.50. The trade was a 32.09% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 3.80% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on ZNTL. Rodman & Renshaw began coverage on shares of Zentalis Pharmaceuticals in a research report on Thursday, July 23rd. They set a “buy” rating and a $11.00 price target on the stock. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Friday, May 22nd. Wall Street Zen lowered Zentalis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research note on Monday, July 6th. Finally, Mizuho started coverage on shares of Zentalis Pharmaceuticals in a report on Friday, July 17th. They set an “outperform” rating and a $8.00 price objective for the company. Four analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $6.75.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.